The FDA has recently approved medical device company OptMed Inc.’s new biosurgical adhesive. It is the first medical adhesive of its kind, since it does not depend on cyanoacrylate chemistry. In addition, the adhesive is the first topical surgical adhesive to be cleared through a process using randomized controlled clinical trials.
The adhesive, dubbed BondEase, will be used to close lacerations and surgical incisions, and will be applied with the aid of a specialized device that will speed curing times. The trials showed that BondEase provided a sound alternative to staples or sutures. It achieved 100% wound closure within 10 days and delivered optimal cosmetic outcomes within 28 days without any significant adverse reactions among the patients who participated in the trial.
This innovation comes at a time when the market for high-strength medical adhesives is expected to experience double digit growth. The BondEase medical adhesives system will be available to the medical profession from late 2016.